 |
Using the SPoT-Light® HER2 CISH Kit and common equipment in the pathology lab, pathologists can now perform a HER2 assay analogous to routine IHC that provides gold-standard HER2 gene status information and improves upon the results obtained by FISH.
 |
| | | | | ||||||||||||||
CISH: A practical alternative to FISH and IHC
|
Become a HER2 CISH certified lab now!
|
SPoT-Light® HER2 CISH Kit
|
Intended Use:
The SPoT-Light® HER2 CISH Kit is intended to quantitatively determine HER2 gene amplification in formalin-fixed, paraffin-embedded (FFPE) breast carcinoma tissue sections using chromogenic in situ hybridization (CISH) and bright-field microscopy. The SPoT-Light® HER2 CISH Kit is indicated as an aid in the assessment of patients for whom Herceptin® (trastuzumab) treatment is being considered. The assay results are intended for use as an adjunct to the clinicopathological information currently being used as part of the management of breast cancer patients. Interpretation of test results must be made within the context of the patient’s clinical history by a qualified pathologist.
SPoT-Light® is a registered trademark of Invitrogen Corporation. Herceptin® is a registered trademark of Genentech, Inc.
The SPoT-Light® HER2 CISH Kit is intended to quantitatively determine HER2 gene amplification in formalin-fixed, paraffin-embedded (FFPE) breast carcinoma tissue sections using chromogenic in situ hybridization (CISH) and bright-field microscopy. The SPoT-Light® HER2 CISH Kit is indicated as an aid in the assessment of patients for whom Herceptin® (trastuzumab) treatment is being considered. The assay results are intended for use as an adjunct to the clinicopathological information currently being used as part of the management of breast cancer patients. Interpretation of test results must be made within the context of the patient’s clinical history by a qualified pathologist.
SPoT-Light® is a registered trademark of Invitrogen Corporation. Herceptin® is a registered trademark of Genentech, Inc.
|